UCB reports financials in line with expectations, integration completed, R&D milestones achieved and stronger focus on core business
BRUSSELS, BELGIUM - August 1st 2008 - 7:00 am CET - press release, regulated information - UCB today announced its consolidated interim financial results.
"The financial performance in the first six months is well in-line with expectations," says Roch Doliveux, CEO of UCB. "With one of the most exciting late stage pipelines in the industry and following recent approvals, like Cimzia® for Crohn's disease in the U.S., and positive opinions for Neupro® for RLS and Vimpat® for epilepsy in Europe, the time is now to further shape UCB and become a specialist company focused on successfully delivering our new medicines to patients."
Stay up-to-date on the latest news and information from UCB